Fernando Bril MDDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
Originally from Argentina, where he did his medical school and internal medicine residency, Dr. Bril moved to USA in 2012. Since then, he has completed a second internal medicine residency, and has been working as a physician-scientist in the field of NAFLD and insulin resistance. Even before starting his Internal Medicine residency, Dr. Bril had a strong interest in clinical research and biostatistics, embarking early-on on a career as a physician-scientist. Dr. Bril’s main research interest has been to understand the metabolic mechanisms that promote the progression from isolated steatosis to NASH and to identify pharmacological approaches that could be used to delay this progression. He has carried out several clinical and translational research studies that have resulted in significant peer-reviewed articles in the field, including 2 randomized controlled trials on the use of pioglitazone alone or combined with vitamin E (Cusi, et al. Annals Intern Med 2016; Bril, et al. Diabetes Care 2019). More specifically, in the last few years, he has carefully examined how the severity of liver disease influences changes in dyslipidemia, diabetes control, and insulin resistance, all mechanisms potentially leading to the increased cardiovascular risk in patients with NAFLD. Dr. Bril and his research group have also focused on the assessment of potential new plasma and imaging biomarkers for the diagnosis of NAFLD.